2024 CTAD Presentation:
ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer’s Disease
2024 AAIC Poster:
INTERCEPT-AD: Understanding the Patient Experience and Expectations for Treatment Through Qualitative Interviews Among Trial Participants with Early Alzheimer’s Disease
and Their Study Partners
2024 AAIC Poster:
Sabirnetug (ACU193) Lowers CSF Levels of Synaptic Biomarkers in INTERCEPT-AD Phase 1 Study in Early AD
2024 AAIC Poster:
INTERCEPT-AD: Development and Qualification of a Highly Sensitive Immunoassay Detecting Total Sabirnetug (ACU193) in Human CSF
2024 AAIC Poster:
INTERCEPT-AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners
2024 ADPD Presentation:
Sabirnetug (ACU193) Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study in Early AD.
Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug (ACU193)-Amyloid Βeta Oligomer Complexes in Human CSF.
2024 AAN Presentation:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
2024 AAN Poster:
A phase 1 study, INTERCEPT-AD, of ACU193: safety, target engagement, and biomarker changes.
